Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose fluticasone for chronic stable asthma
NCT00695604Phase 2
Key facts
- Status
- Withdrawn
- Start
- May 2008
- Primary completion
- Sep 2011
- Countries
- 1
- Sponsor
- University of Chicago
- Modality
- Orthosteric Ligands
- Drugs
- fluticasone
- Conditions
- asthma
01
Overview
Phase 2, randomised, double-blind trial of fluticasone in asthma (2 arms), sponsored by University of Chicago. Primary endpoint: Airflow inflammation. Planned start May 2008; status: withdrawn.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Placebo Arm
Placebo MDI + Albuterol MDI
Active Arm
Fluticasone MDI + Albuterol MDI
03
Who it enrols
Adults aged 18-50 with a physician diagnosis of asthma and evidence of airflow obstruction, currently treated with daily ICS/LABA and as-needed SABA.
04
Endpoints
Primary
Airflow inflammation
Secondary
Airflow obstruction
Beyond the preview
Go deeper on NCT00695604.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00695604.